Pharmaceuticals Italy

Italy Anxiety Disorder Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Italy Anxiety Disorder Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Disorder, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Italy · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $297.4 Mn Placeholder estimate
Estimate 2025 $304.8 Mn 2.6% of the global market
Projected 2034 $380.6 Mn 24.9% Adds $75.9 Mn over 9 forecast years
CAGR 2025–2034 2.5% Faster than 2% of 183 Pharmaceuticals markets here
Key players 5
  • Italy is 2.61% of the global market.
  • In Europe, the largest is Germany at $476.1 Mn.
  • Fastest growing: Russia at 2.9% a year.
  • Italy ranks 2nd of 6 by size in Europe.

Market size projection

Italy

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$75.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Anxiety Disorder Drugs Market market size by year, Italy
YearMarket sizeChange that yearSince 2025
2024 (estimate) $297.4 Mn — —
2025 (base) $304.8 Mn +$7.4 Mn —
2026 (forecast) $312.4 Mn +$7.6 Mn +2.5%
2027 (forecast) $320.2 Mn +$7.8 Mn +5.1%
2028 (forecast) $328.2 Mn +$8.0 Mn +7.7%
2029 (forecast) $336.4 Mn +$8.2 Mn +10.4%
2030 (forecast) $344.8 Mn +$8.4 Mn +13.1%
2031 (forecast) $353.5 Mn +$8.6 Mn +16%
2032 (forecast) $362.3 Mn +$8.8 Mn +18.9%
2033 (forecast) $371.4 Mn +$9.1 Mn +21.8%
2034 (forecast) $380.6 Mn +$9.3 Mn +24.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Italy Anxiety Disorder Drugs Market Analysis at a glance
Market size, 2025$304.8 Mn placeholder estimate
Forecast, 2034$380.6 Mn placeholder estimate
Growth (CAGR), 2025–20342.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledAnxiolytic Drugs
SegmentsDrug class, disorder and end user (see all)
Key playersPfizer Inc., Eli Lilly and Company, Viatris, Lundbeck, MindMed (see all)
Regulator in ItalyAIFASource: Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
Active clinical trials31 in ItalySource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Italy Anxiety Disorder Drugs Market Analysis Executive Summary

Anxiety disorder drugs treat generalised anxiety, panic and social anxiety with antidepressants, buspirone and other medicines.

Key segments of the anxiety Disorder Drugs market include drug class (SSRIs, SNRIs and Benzodiazepines) and disorder (Generalized Anxiety, Panic Disorder and Social Anxiety).

Bar chart: Italy Anxiety Disorder Drugs market size, 2024–2034, placeholder estimates. $297.4 Mn in 2024, $304.8 Mn in 2025 and $380.6 Mn in 2034, 2.5% CAGR.
Italy Anxiety Disorder Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Italy Anxiety Disorder Drugs Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the anxiety Disorder Drugs market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the anxiety Disorder Drugs market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the anxiety Disorder Drugs market.

Competitive Landscape for Anxiety Disorder Drugs Market in Italy

The anxiety Disorder Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Anxiety Disorder Drugs Market in Italy

Anxiety Disorder Drugs in Italy: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement.⁠[1] The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for.⁠[2] ClinicalTrials.gov lists 31 studies on Anxiety Disorder Drugs that are recruiting, active or about to start in Italy.⁠[3] Suicide rate: 7.2 per 100,000 people in 2023, the latest WHO figure for Italy.⁠[4]

[1] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[2] Italian Ministry of Health. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 21 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for anxiety Disorder Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Italy.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Anxiety Disorder Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Anxiety Disorder Drugs in context

Italy compared

  • Suicide rate: 7.2 per 100,000 people (2023). World: 9.2 per 100,000 people (2023). 12th highest of the 13 countries we cover in Europe.[1]
  • Health spending per person: 3,398 US$ per person (2024). World: 1,317 US$ per person (2023). 9th highest of the 13 countries we cover in Europe.[2]
  • Doctors: 4.19 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 7th highest of the 13 countries we cover in Europe.[3]

[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 22 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

Free data on this topic

Inside Italy

Quick answers

Frequently asked questions

How big is the Anxiety Disorder Drugs market in Italy?
Placeholder estimate: about $304.8 Mn in 2025, rising to about $380.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Anxiety Disorder Drugs market in Italy growing?
Placeholder estimate: about 2.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Anxiety Disorder Drugs market report cover?
The report splits the market by drug class (SSRIs, SNRIs, Benzodiazepines, Buspirone and more), disorder (Generalized Anxiety, Panic Disorder, Social Anxiety) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Anxiety Disorder Drugs market?
Key players include Pfizer Inc., Eli Lilly and Company, Viatris, Lundbeck and MindMed.
What is driving the Anxiety Disorder Drugs market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the anxiety Disorder Drugs market. Governments and employers are investing more in mental health care.
Who regulates Anxiety Disorder Drugs in Italy?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement. Source: Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
How is healthcare paid for in Italy?
The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for. Source: Italian Ministry of Health. Checked 14 Nov 2026.
How many clinical trials on Anxiety Disorder Drugs are running in Italy?
31 studies are recruiting, active or about to start in Italy, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.
What does WHO report for Italy?
Suicide rate: 7.2 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 21 Nov 2026.
How many people in Italy are 65 or older?
25.1% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 21 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Italy

See all

Related on mental health

See the topic